Evidence map›Paper›PMID 37241027›Full record

ArticleJournal of personalized medicine2023

Highly Selective Targeting of Pancreatic Cancer in the Liver with a Near-Infrared Anti-MUC5AC Probe in a PDOX Mouse Model: A Proof-of-Concept Study.

Michael A Turner, Kristin E Cox, Nicholas Neel, Siamak Amirfakhri, Hiroto Nishino, Bryan M Clary, Mojgan Hosseini, Gopalakrishnan Natarajan, Kavita Mallya, Aaron M Mohs and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Michael A TurnerDivision of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.ORCID 0000-0001-8949-3136
Kristin E CoxDivision of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.ORCID 0000-0001-8621-1869
Nicholas NeelDivision of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.
Siamak AmirfakhriDivision of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.
Hiroto NishinoDivision of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.
Bryan M ClaryDivision of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.
Mojgan HosseiniDepartment of Pathology, University of California San Diego, La Jolla, CA 92037, USA.
Gopalakrishnan NatarajanDepartment of Biochemistry, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Kavita MallyaDepartment of Biochemistry, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Aaron M MohsDepartment of Biochemistry, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Robert M HoffmanDivision of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.ORCID 0000-0002-0049-0041
Surinder K BatraDepartment of Biochemistry, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0001-9470-9317
Michael BouvetDivision of Surgical Oncology, Department of Surgery, University of California San Diego, La Jolla, CA 92037, USA.ORCID 0000-0002-0086-2159
University of California San Diego · USUniversity of Nebraska Medical Center · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Molecular Imaging Probe(s) for Optical Surgical Navigation of Pancreatic CancerR01CA256973 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Surinder K. Batra, Michael Bouvet · 2022 to 2026
$2.2M
NCI NIH HHS CCSG Grant P30CA23100).NCI NIH HHS R01 CA256973NCI NIH HHS T32 CA121938NIH HHS 1 R01 CA256973-01A1NIH HHS T32CA121938
6 · The paper itself

Abstract

Accurately identifying metastatic disease is critical to directing the appropriate treatment in pancreatic cancer. Mucin 5AC is overexpressed in pancreatic cancer but absent in normal pancreas tissue. The present proof-of-concept study demonstrates the efficacy of an anti-mucin 5AC antibody conjugated to an IR800 dye (MUC5AC-IR800) to preferentially label a liver metastasis of pancreatic cancer (

Indexed as

fluorescent antibodyimagingliver metastasismucinpancreatic cancerselective targeting

Identifiers

PMID37241027
PMCPMC10221372
OpenAlexW4377294102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.